https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=9727
No pharmaceutical opinion available for this interaction.
Elvitegravir / Cobicistat may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.
–
–
–
Probably without any clinical consequence.
No a priori dosage adjustment is recommended.
Monitor for adverse effects.
See comments for further details.
–
–
–
Reference number |
---|
# patients |
HIV |
Dose |
Frequency |
AUC |
Cmin |
Cmax |
3360 |
---|
10 |
- |
150/150 mg |
QD |
+ 2% |
- 2% |
- 6% |
3360 |
---|
10 |
- |
10 mg |
x 1 |
+ 38% |
+ 43% |
+ 89% |
Ref #3360, 2570 and 3281 : The increase in AUC ranged from 48-142% and the increase in AUC ranged from 13-67% depending on the subject under study.
Likely driven by inhibition of intestinal efflux by BCRP or hepatic uptake by OATPs by EVG/c. No serious adverse events or grade 2, 3 or 4 AEs or grade 3 or 4 laboratory abnormalities occurred.
The study used as a reference a concentration of rosuvastatin alone with the equivalence limits of 70-143% for AUC and 70-175% for Cmax.
The modest increase observed is considered clinically insignificant. Elvitegravir/cobicistat can be taken with rosuvastatin.